Background: Surgery for complex primary and metastatic colorectal cancer (CRC), such as liver resection and hyperthermic intraperitoneal chemotherapy (HIPEC), in academic settings has led to improved survival but is associated with complications up to 75%. Prehabilitation has been shown to prevent complications in non-academic hospitals. This pilot study aimed to determine the feasibility and potential efficacy of a multimodal prehabilitation program in patients undergoing surgery in an academic hospital for complex primary and metastatic CRC.

Methods: All patients awaiting complex colorectal surgery, liver resection, or HIPEC from July 2019 until January 2020 were considered potentially eligible. Feasibility was measured by accrual rate, completion rate, adherence to the program, satisfaction, and safety. To determine potential efficacy, postoperative outcomes were compared with a historical control group.

Results: Sixteen out of twenty-five eligible patients (64%) commenced prehabilitation, and fourteen patients fully completed the intervention (88%). The adherence rate was 69%, as 11 patients completed >80% of prescribed supervised trainings. No adverse events occurred, and all patients expressed satisfaction with the program. The complication rate was significantly lower in the prehabilitation group (37.5%) than the control group (70.2%, = 0.020). There was no difference in the type of complications.

Conclusion: This pilot study illustrates that multimodal prehabilitation is feasible in the majority of patients undergoing complex colorectal cancer, liver resection, and HIPEC in an academic setting.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047129PMC
http://dx.doi.org/10.3390/cancers15061870DOI Listing

Publication Analysis

Top Keywords

liver resection
16
multimodal prehabilitation
12
patients undergoing
12
complex colorectal
12
pilot study
12
potential efficacy
12
patients
8
undergoing complex
8
colorectal surgery
8
surgery liver
8

Similar Publications

LRP4 mutations promote tumour progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma.

Hepatology

December 2024

Department of Liver Surgery and Transplantation, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

Background And Aims: Hepatocellular carcinoma (HCC) recurrence is a major factor limiting long-time survival and the cause of most deaths in patients with HCC. However, molecular characterisation and potential therapeutic targets of recurrent HCC remain mostly unknown.

Approach And Results: We performed whole-exome sequencing (WES) in 63 matched primary and recurrent HCC tumours and combined the data with whole-genome sequencing (WGS) results in 43 paired samples from our previous study.

View Article and Find Full Text PDF

Primary liver cancer, predominantly hepatocellular carcinoma (HCC), is a leading cause of cancer-related mortality. Tumor thrombus (TT) in the inferior vena cava (IVC) or right atrium (RA) significantly worsens prognosis. We present four cases of male patients (average age 57) with HCC and TT extending into the IVC/RA, treated at our center.

View Article and Find Full Text PDF

Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a rare and highly aggressive malignancy characterized by both exocrine and neuroendocrine components. Treatment options for metastatic cases are limited, with typical therapeutic approaches involving a combination of chemotherapy and immunotherapy. A 68-year-old male with metastatic gastric MANEC was treated with targeted therapy, immunotherapy, and chemotherapy, including S-1, apatinib, cadonilimab, and paclitaxel.

View Article and Find Full Text PDF

While orbital floor metastasis from hepatocellular carcinoma (HCC) has been reported, ocular (eyeball) metastasis is exceedingly rare. Most ocular metastases originate from breast or lung cancer. In this article, we present the case of a 65-year-old man diagnosed with HCC with central necrosis (cT3N0M0, stage III) based on characteristic imaging findings.

View Article and Find Full Text PDF

Primary Retroperitoneal Seminoma-An Uncommon Presentation With Significant Implications.

Case Rep Surg

December 2024

Institute of Surgical Gastroenterology, GI and HPB Oncosurgery and Liver Transplant, Sir Ganga Ram Hospital, New Delhi, India.

Primary retroperitoneal seminoma is an exceedingly rare type of germ cell tumor, accounting for less than 5% of all such tumors. These tumors are typically large at presentation due to their slow growth and the nonspecific nature of symptoms, which often leads to delayed diagnosis. A 40-year-old male presented with intermittent abdominal pain and a palpable lump in the right paraumbilical region.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!